View Post

ADC Choices Require Discretion in HER2-Negative MBC

In In The News by Barbara Jacoby

By: Kyle Doherty From: onclive.com With multiple antibody drug conjugate (ADC) options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies, according to a presentation by Joshua Z. Drago, MD, MS, during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow® conference.1 “ADCs are being developed …

View Post

ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: targetedonc.com CASE SUMMARY A 56-year-old, postmenopausal woman presents with a palpable right breast mass with no clinically abnormal axillary lymph nodes. Core biopsy showed the patient had grade II invasive ductal carcinoma (IDC), was estrogen receptor-positive (ER+)/progesterone receptor-positive (PR+), and had HER2 immunohistochemistry (IHC) of 0; Ki-67 was at 33%. Lumpectomy and sentinel lymph node (SLN) biopsy showed a …

View Post

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

In In The News by Barbara Jacoby

By: By Dr. Chinta Sidharthan From: news-medical.net In a recent study published in the BMJ Journal, a team of scientists from China investigated the safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib, a pan-HER inhibitor, in combination with docetaxel and trastuzumab, and compared it to that of a variety of a …

View Post

Dato-DXd Induces Significantly Improved PFS in HR+, HER2- Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Kristie L. Kahl From: targetedonc.com Treatment with datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared with chemotherapy, in patients with hormone receptor-positive, HER2-low or -negative metastatic breast cancer, according to data from the pivotal phase 3 TROPION-Breast01 trial (NCT05104866) presented at ESMO Congress 2023.1,2 “Overall results support Dato-DXd as a potential …

View Post

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

In In The News by Barbara Jacoby

By: Courtney Flaherty From: onclive.com Despite the ever-growing landscape of therapeutics for patients with estrogen receptor (ER)–positive metastatic breast cancer beyond the first line, there is still a substantial need for effective options for those who develop resistance to standard endocrine therapies through multiple mechanisms. Due to its unique mechanism of action, adding the selective eIF4A inhibitor zotatifin (eFT226) to …

View Post

No New Safety Concerns Are Identified With Subcutaneous Trastuzumab in HER+ Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Kyle Doherty From: oncnursingnews.com Subcutaneous trastuzumab (Herceptin) demonstrated a safety profile similar to that of intravenous trastuzumab, according to findings from the final analysis of the phase 3 MetaspHER trial (NCT01810393) published in Clinical Breast Cancer.1 Of note, no new concerns related to prolonged exposure in patients with HER2-positive metastatic breast cancer emerged. During the study treatment period (cycles 1-18), patients …

View Post

Jennifer Plichta, MD, on Improved Staging for De Novo Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Jeff Minerd From: medpagetoday.com A novel prognostic staging system for patients with de novo metastatic breast cancer (dnMBC) reflects improved outcomes for this disease, accurately summarizes prognosis, and facilitates patient-provider communication, researchers reported in the Journal of Clinical Oncology. Although the American Joint Commission on Cancer (AJCC) revised staging guidelines for breast cancer in 2016, “this did not include …

View Post

What is metastatic breast cancer and how is it treated?

In In The News by Barbara Jacoby

By: Maryam B. Lustberg, MD, MPH From: medicalxpress.com Metastatic breast cancer can be a daunting diagnosis, but the prognosis has improved somewhat with advances in treatment. Also known as stage 4 breast cancer, metastatic cancer is defined as the spread of disease beyond the local breast and nearby lymph nodes. More than 150,000 individuals in the United States are living …

View Post

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

In In The News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The National Comprehensive Cancer Network (NCCN) Guidelines now recommend the use of 18F-Fluorestradiol (18F-FES; Cerianna) positron emission tomography (PET) in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor (ER)–positive breast cancer.1 This inclusion in the NCCN Guidelines comes after the publication of the October 2022 Appropriate Use …

View Post

Trastuzumab Deruxtecan Elicits Superior HRQOL in HER2+ Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Caroline Seymour From: onclive.com Patient-reported outcomes, including time to definitive deterioration of global health status and overall quality of life (QOL) with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic breast cancer reflected the regimen’s favorable risk-benefit profile in the phase 3 DESTINY-Breast02 trial (NCT03523585), according to findings presented during the 2023 ESMO Breast Cancer Annual Congress. Global health status and …